Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC 22 therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer 23 immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the 24 maturation and activation of DCs. Therefore, human clinical outcomes with DC therapy alone have 25 been disappointing. In this study, we use fully serotype 3 oncolytic adenovirus Ad3-hTERT-CMV-26 hCD40L, expressing human CD40L, to modulate the tumor microenvironment with subsequently 27 improved function of DCs. We evaluated the synergistic effects of Ad3-hTERT-CMV-hCD40L and 28 DCs in the presence of human peripheral blood mononuclear cells ex vivo and in vivo. Tumors treated 29 with Ad3-hTERT-CMV-hCD40L and DCs featured greater antitumor effect compared with unarmed 30 virus or either treatment alone. 100% of humanized mice survived to the end of the experiment, while 31 mice in all other groups died by day 88. Moreover, adenovirally-delivered CD40L induced activation 32 of DCs, leading to induction of Th1 immune responses. These results support clinical trials with Ad3-33 hTERT-CMV-hCD40L in patients receiving DC therapy.
The field of cancer immunotherapy has made tremendous progress recently and it has become a first first in the presence of Ad3-hTERT-E1A and Ad3-hTERT-CMV-hCD40L infected cells, and second 150 in the presence of cell culture media supernatants collected from virus-infected cells. 151 In the first assay, A549 cells were infected with Ad3-hTERT-E1A, Ad3-hTERT-CMV-hCD40L, or 152 left uninfected. The cells were washed after 18h with PBS, and the infection media was replaced with 153 fresh media containing monocyte-derived immature DCs. After 48h, maturation status of the DCs 154 was assessed using flow cytometry. After this T cells isolated from fresh PBMCs through Pan T cell 155 Isolation kit (Miltenyi Biotec, 130-096-535) were added to the mixture of DCs and virus-infected 156 tumor cells. After 24h, T-cell activation was assessed with flow cytometry (see Supplementary Table   157 1 for the list of antibodies). 158 In the second assay, A549 cells were first infected with Ad3-hTERT-CMV-CD40L or Ad3-hTERT-
159
E1A and supernatants were collected and filtered to remove the viruses 48 hours later. Figure 1A ).
262
The double therapy or the triple therapy showed significant anti-tumor effect as compared with mock 263 group (p<0.0001). However, tumor control was best in the group treated with hCD40L-armed virus, 264 PBMCs, and DCs (Ad3-hTERT-E1A + PBMCs +DCs Vs Ad3-hTERT-CMV-hCd40L + PBMCs 265 +DCs p< 0.001).
266
Cancer specific survival data ( Figure 4B and Supplementary Figure 1B ) mirrored tumor control data.
267
Mice treated with hCD40L-armed virus, PBMCs, and DCs showed a significant improvement in Moreover, infiltration of significantly high levels of B and T lymphocytes in the same groups were 277 also observed ( Figure 5D and 5E). The immune modulation of the tumor microenvironment towards 278 Th1 phenotype was further confirmed through the presences of high levels of TNF alpha, IFN 279 gamma, IL2, IL12, granzyme B and IL6 in the same groups ( Supplementary Figure 3) . In summary, 280 our findings suggest that expression of CD40L in the tumor induces maturation of DCs, leading to 281 activation of adaptive immune response against the tumor. In preclinical studies, it has been reported that murine CD40L upregulates DC co-stimulatory PBMCs was more prominent compared with single agent treatments. As expected, CD40+ tumor 336 cells treated with Ad3-hTERT-CMV-hCD40L, DCs, and PBMCs were more susceptible to the 337 treatment compared to the CD40-tumor cells, although cell killing was achieved also in this group.
338
This is in accordance with our previous findings, indicating that potential application of this virus is 339 not restricted to CD40+ tumors [36] .
340
Next, we tested the ability of Ad3-hTERT-CMV-hCD40L to sensitize the tumor microenvironment that death due to cancer could be prevented in 100% of mice in the key experimental group.
357
In summary, we provide preclinical proof of principle for using Ad3-hTERT-CMV-hCD40L in PBMCs were injected intravenously on day 0 (dashed arrow). Viruses (gray arrows) were injected at 416 1 X 10 8 VP and DCs (black arrows), 1X10 6 , were injected intratumorally three times alternatively. 
